CD274 and neoplasm: Preclinical studies demonstrate sugemalimab’s preserved Fcγ receptor I (FcγRI) binding capacity drives PD-L1+ tumor cell phagocytosis via macrophage engagement, while potentially augmenting tumor antigen cross-presentation (42, 43).